Resources & Guides

A semaglutide constipation guide built on the Wegovy label, covering the mechanism, label-verified incidence, relief strategies, and when constipation becomes an emergency.

A semaglutide nausea management guide built on the Wegovy label's own numbers and escalation language, not generic tips.

A tirzepatide constipation guide covering the mechanism, brand-correct FDA label rates for Mounjaro and Zepbound, relief strategies, and when constipation becomes an emergency.

The oral Wegovy tablet carries the same GLP-1 side effect profile as the rest of the class, but the FDA label handles it differently from the injection. The pen gets a full per-symptom adverse reaction table. The tablet does not. This guide covers what the label actually reports for each format, the dose-ladder timing of GI symptoms, discontinuation rates, the boxed warning, and management strategies.

With commercial coverage of the Zepbound single-dose pen and the savings card, eligible patients pay as little as $25 per fill, with savings capped at $1,300 per calendar year on that tier. Medicare beneficiaries have a new route from July 1, 2026: the CMS GLP-1 Bridge, which covers the Zepbound KwikPen only at $50 a month. This guide covers the insured path, prior authorization, and appeals.

There is no FDA-approved tirzepatide pill, and the reason is structural rather than a matter of timing. Tirzepatide is a peptide that stomach acid and digestive enzymes break down before it can be absorbed, which is why Mounjaro and Zepbound remain once-weekly injections. This guide covers why, what the approved oral GLP-1 pills actually are, and why orforglipron (Foundayo) is a different molecule rather than tirzepatide in tablet form.

Rybelsus is the semaglutide pill: the first GLP-1 receptor agonist ever approved as a swallowable tablet. This guide covers the 3, 7, and 14 mg dose ladder, the SNAC absorption enhancer that makes an oral peptide possible at all, the strict empty-stomach rules, what the tablet is and is not approved to treat, and where Rybelsus stands in 2026 as US prescriptions transition to the reformulated Ozempic pill.

There is now an oral Wegovy pill: a once-daily 25mg semaglutide tablet FDA-approved on December 22, 2025 for weight management, the first oral GLP-1 cleared for weight loss. This guide covers the dose ladder, the empty-stomach rule, the OASIS-4 results, how it compares to the injectable pen, and why it is a separate product from the diabetes-only Ozempic pill.

Ozempic is an FDA-approved prescription drug with a normal legal pathway. This guide walks the full process, prescriber to pharmacy, and shows how coverage hinges on the diagnosis.

Semaglutide mimics a natural gut hormone to reduce hunger, slow digestion, and signal the brain to stop eating. This article explains exactly how each mechanism works and why the weekly injection lasts all week.

Mounjaro is tirzepatide; semaglutide is Ozempic and Wegovy. Compare mechanism, SURMOUNT-5 trial data, side effects, FDA indications, and dosing side by side.

Everything you need to know about semaglutide (Ozempic/Wegovy): GLP-1 mechanism, FDA-approved dosing protocols, half-life pharmacokinetics, side effects, and our free calculator to track your journey.

Retatrutide side effects guide: nausea, diarrhea, and other GI symptoms from Phase 2 clinical trial data, plus management strategies.

There is now an oral Ozempic pill: once-daily semaglutide tablets (1.5, 4, and 9 mg) that launched in the United States on May 4, 2026. This guide covers what it is approved for, how it differs from the injectable Ozempic pen, why it is the renamed successor to Rybelsus, and why the oral option for weight loss is the separate Wegovy pill, not the Ozempic pill.

Ozempic and Wegovy list at $900–$1,865 a month, but few patients pay that. This guide walks through every semaglutide cost lever: manufacturer savings cards, NovoCare direct self-pay, commercial insurance, Medicare Part D's obesity exclusion, and how brand-name semaglutide compares to tirzepatide on cash-pay access. Includes a 2026 reality check on what happened to compounded semaglutide.

This Ozempic-specific cost guide walks the list price, commercial insurance, Medicare Part D, and the 2026 NovoCare self-pay ladder, plus why the diabetes-versus-weight-loss distinction drives most of what you actually pay.

People search "GLP-3 retatrutide" after hearing the nickname online. There is no GLP-3 receptor. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon. Here is where the name came from and what it means.

There is no formal drug-drug interaction study between retatrutide and alcohol. What we have is a clear pharmacological mechanism, one peer-reviewed animal study, and class-level precedent from approved GLP-1 drugs. Here is what the evidence actually says.

An educational, pharmacokinetics-grounded explainer of what a tirzepatide to retatrutide transition involves: washout timing, the 2mg restart, GI reset, and the investigational reality.

A practical retatrutide nausea management guide covering the mechanism, Phase 2 trial data, the dose step-back protocol, and dietary strategies.

One chart, all the numbers that matter. Zepbound (tirzepatide) and Wegovy (semaglutide) compared row by row using SURMOUNT-5 head-to-head data, dosing ladders, cost, and FDA approvals.

A side-by-side look at the single, dual, and triple agonists. Trial weight loss runs 14.9% (semaglutide), 20.9% (tirzepatide), and 24.2% (retatrutide), but the trials differ and only one pairing has a head-to-head study.

"GLP-3" is informal shorthand for triple-agonist drugs like retatrutide. This chart maps GLP-1 mono, GIP/GLP-1 dual, and triple agonists side by side on mechanism, FDA status, and trial weight loss.

Retatrutide activates three hormone receptors at once. Here is what it actually does inside the body: appetite suppression, metabolic shifts, blood sugar regulation, and fat loss, all grounded in published Phase 2 data.

Mounjaro (tirzepatide) treats type 2 diabetes by activating two incretin receptors at once. Here is the organ-level physiology, the SURPASS-1 evidence behind its 2022 FDA approval, and how it compares to Ozempic in head-to-head trials.

A practical how-to guide for running a GLP-1 microdosing protocol across semaglutide, tirzepatide, and retatrutide. Covers approach selection, compound-specific steps, titration decisions, and calculator modeling.

The Zepbound KwikPen list price is $1,086.37 a month without insurance. The LillyDirect Self Pay Journey Program (launched February 2026) brings cash-pay vials down to $299 for 2.5mg, $399 for 5mg, and a flat $449 for every dose from 7.5mg to 15mg. This guide covers Zepbound pricing only, with no Mounjaro overlap.

A focused 5mg-vial reference for semaglutide reconstitution. Includes the two standard BAC water options (2mL and 2.5mL), the IU chart for every weekly dose from 0.25mg through 2.4mg, vial longevity math, the U-100 syringe capacity warning at the Wegovy maintenance dose, storage windows, and the U.S. regulatory context for compounded semaglutide in 2026.

Complete tirzepatide dosage chart showing Mounjaro and Zepbound titration protocols week-by-week from 2.5mg to 15mg. Includes what to expect at each dose level, side effects by tier, printable download, and a free dosing calculator.

What microdosing GLP-1 actually means, how it differs from standard titration, what clinical evidence exists, and the risks of using sub-standard doses of semaglutide, tirzepatide, or retatrutide.

A pharmacokinetics-grounded guide to switching from semaglutide (Ozempic/Wegovy) to tirzepatide (Mounjaro/Zepbound), covering washout timing, dosing on restart, and outcomes.

Complete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.

Everything you need to know about microdosing GLP-1 agonists. Split dosing protocols for retatrutide, tirzepatide, and semaglutide to reduce side effects without sacrificing weight loss results.

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

The ultimate retatrutide resource hub. Learn about this investigational triple-agonist, its remarkable Phase 2 results, dosing schedules, microdosing protocols, and use our free calculator to plan your journey.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

Unlike semaglutide and tirzepatide, compounded retatrutide is explicitly prohibited under federal law — there is no approved version, so the shortage exemption never applied. This guide explains the legal reality, what's actually in research-peptide vials, and what your real options are.

Retatrutide has no official price. It's still in Phase 3 clinical trials. This guide covers what people actually pay today for research peptides and compounded retatrutide, what it will likely cost at commercial launch, and how it compares to tirzepatide and semaglutide.

Mounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.

Zepbound and Ozempic are approved for different conditions. Zepbound targets weight management; Ozempic targets type 2 diabetes. Compare tirzepatide vs semaglutide across mechanisms, trial results, dosing, and cost.

Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) on both HbA1c reduction and weight loss in the SURPASS-2 trial. Ozempic holds the cardiovascular edge. Full comparison inside.

SURMOUNT-5 compared tirzepatide and semaglutide head-to-head for the first time. See the weight loss numbers, mechanism differences, dosing schedules, and which drug may fit your situation.

Zepbound side effects guide: nausea 25-29%, diarrhea 19-23%, symptom timeline, serious warnings, and practical management tips for weight loss patients.

Zepbound contains tirzepatide, a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Here is exactly what happens in your body, what SURMOUNT-1 showed at 72 weeks, and why the 5-day half-life matters for your dose schedule.

Free tirzepatide dosing calculator plus complete guide. Visualize Mounjaro/Zepbound drug levels, plan titration schedules, understand half-life pharmacokinetics, and manage side effects.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.

How much weight can you lose on semaglutide? STEP 1 trial data shows 14.9% mean body weight loss at 68 weeks, with 86.4% of participants losing at least 5%. This guide breaks down the clinical evidence, month-by-month timeline, real-world results, and what factors determine your outcome.

Tirzepatide list price runs over $1,000/month—but what you actually pay can be far less. This guide covers every pricing tier: Mounjaro and Zepbound pens, LillyDirect self-pay vials, insurance and savings cards, Medicare, and where compounded tirzepatide stands after the FDA's 2025 ruling. Includes a cost-per-mg breakdown tied to dose optimisation.

Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes and obesity. It's the active ingredient in Ozempic, Rybelsus, and Wegovy. This guide explains what it is, how it works, what the clinical trials show, and who qualifies for treatment.

Tirzepatide activates two hormone receptors — GLP-1 and GIP — producing greater fat loss than GLP-1-only drugs. Here's what each receptor does, why the mechanism isn't fully understood, and what the clinical trials show.

Retatrutide achieved 24.2% weight loss vs semaglutide's 14.9% in trials. Compare triple-agonist vs single-agonist mechanisms, approval status, clinical data, side effects, and find out which GLP-1 medication is right for you.

Retatrutide is the first triple agonist that activates GIP, GLP-1, and glucagon receptors at once. How each receptor contributes to weight loss, why it outperforms single and dual agonists, and what the clinical data shows.

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.

Complete guide to tirzepatide weight loss: SURMOUNT trial results showed 20.9% average weight loss at 72 weeks on 15mg dose. How it works, what to expect, timeline, dosing, comparison with Ozempic/Wegovy, and managing side effects.

Tirzepatide achieved 20.9% weight loss vs semaglutide's 14.9% in clinical trials. The SURPASS-2 head-to-head trial showed tirzepatide superior on both A1C and weight. Compare mechanisms, side effects, dosing, costs, and which GLP-1 medication fits your situation.

Both Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.

Complete semaglutide dosage chart showing Ozempic (1.0 mg max) and Wegovy (2.4 mg maintenance, 7.2 mg max) titration protocols week-by-week. Includes what to expect at each dose level, side effects data, printable download, and a free dosing calculator.

Semaglutide side effects guide: nausea, diarrhea, and GI symptoms from STEP and SUSTAIN trials, plus practical management tips.

Tirzepatide side effects guide: nausea, diarrhea, and other GI symptoms from clinical trial data, plus practical management tips.